Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.

Fu J, Si P, Zheng M, Chen L, Shen X, Tang Y, Li W.

Bioorg Med Chem Lett. 2012 Nov 15;22(22):6848-53. doi: 10.1016/j.bmcl.2012.09.045. Epub 2012 Sep 23.

PMID:
23040732
2.

Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.

Wang L, Si P, Sheng Y, Chen Y, Wan P, Shen X, Tang Y, Chen L, Li W.

Chem Biol Drug Des. 2015 Apr;85(4):481-7. doi: 10.1111/cbdd.12432. Epub 2014 Oct 10.

PMID:
25228339
3.

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).

Merk D, Gabler M, Gomez RC, Flesch D, Hanke T, Kaiser A, Lamers C, Werz O, Schneider G, Schubert-Zsilavecz M.

Bioorg Med Chem. 2014 Apr 15;22(8):2447-60. doi: 10.1016/j.bmc.2014.02.053. Epub 2014 Mar 15.

PMID:
24685112
4.

Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.

Nicolaou KC, Evans RM, Roecker AJ, Hughes R, Downes M, Pfefferkorn JA.

Org Biomol Chem. 2003 Mar 21;1(6):908-20.

PMID:
12929628
5.

Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.

Sindhu T, Srinivasan P.

Mol Biosyst. 2015 May;11(5):1305-18. doi: 10.1039/c5mb00137d.

PMID:
25787676
6.

Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.

Han KC, Kim JH, Kim KH, Kim EE, Seo JH, Yang EG.

Anal Biochem. 2010 Mar 15;398(2):185-90. doi: 10.1016/j.ab.2009.11.008. Epub 2009 Nov 12.

PMID:
19913492
7.

Farnesoid X receptor: from medicinal chemistry to clinical applications.

Fiorucci S, Mencarelli A, Distrutti E, Zampella A.

Future Med Chem. 2012 May;4(7):877-91. doi: 10.4155/fmc.12.41. Review.

PMID:
22571613
8.

Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.

Deng G, Li W, Shen J, Jiang H, Chen K, Liu H.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5497-502. doi: 10.1016/j.bmcl.2008.09.027. Epub 2008 Sep 10.

PMID:
18815030
9.

Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.

Kainuma M, Makishima M, Hashimoto Y, Miyachi H.

Bioorg Med Chem. 2007 Apr 1;15(7):2587-600. Epub 2007 Jan 31.

PMID:
17292610
10.

Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.

Grienke U, Mihály-Bison J, Schuster D, Afonyushkin T, Binder M, Guan SH, Cheng CR, Wolber G, Stuppner H, Guo DA, Bochkov VN, Rollinger JM.

Bioorg Med Chem. 2011 Nov 15;19(22):6779-91. doi: 10.1016/j.bmc.2011.09.039. Epub 2011 Sep 29.

11.

Farnesoid X receptor regulates bile acid-amino acid conjugation.

Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK.

J Biol Chem. 2003 Jul 25;278(30):27703-11. Epub 2003 May 16.

12.

Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.

Flesch D, Gabler M, Lill A, Gomez RC, Steri R, Schneider G, Stark H, Schubert-Zsilavecz M, Merk D.

Bioorg Med Chem. 2015 Jul 1;23(13):3490-8. doi: 10.1016/j.bmc.2015.04.035. Epub 2015 Apr 18.

PMID:
25934227
13.

Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity.

Steri R, Achenbach J, Steinhilber D, Schubert-Zsilavecz M, Proschak E.

Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.

PMID:
22414727
14.

Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.

Merk D, Steinhilber D, Schubert-Zsilavecz M.

Future Med Chem. 2012 May;4(8):1015-36. doi: 10.4155/fmc.12.47. Review.

PMID:
22650242
15.

Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.

Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S.

Curr Med Chem. 2010;17(2):139-59. Review.

PMID:
19941473
16.

The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression.

Suzuki T, Tamehiro N, Sato Y, Kobayashi T, Ishii-Watabe A, Shinozaki Y, Nishimaki-Mogami T, Hashimoto T, Asakawa Y, Inoue K, Ohno Y, Yamaguchi T, Kawanishi T.

J Pharmacol Sci. 2008 Jul;107(3):285-94. Epub 2008 Jul 5.

17.

Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.

Marinozzi M, Carotti A, Sansone E, Macchiarulo A, Rosatelli E, Sardella R, Natalini B, Rizzo G, Adorini L, Passeri D, De Franco F, Pruzanski M, Pellicciari R.

Bioorg Med Chem. 2012 Jun 1;20(11):3429-45. doi: 10.1016/j.bmc.2012.04.021. Epub 2012 Apr 20.

PMID:
22564381
18.

Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.

Sepe V, Distrutti E, Limongelli V, Fiorucci S, Zampella A.

Future Med Chem. 2015;7(9):1109-35. doi: 10.4155/fmc.15.54. Review.

PMID:
26132522
19.

Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.

Yang L, Broderick D, Jiang Y, Hsu V, Maier CS.

Biochim Biophys Acta. 2014 Sep;1844(9):1684-93. doi: 10.1016/j.bbapap.2014.06.007. Epub 2014 Jun 18.

20.

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.

Fiorucci S, Mencarelli A, Palladino G, Cipriani S.

Trends Pharmacol Sci. 2009 Nov;30(11):570-80. doi: 10.1016/j.tips.2009.08.001. Epub 2009 Sep 14. Review.

PMID:
19758712

Supplemental Content

Support Center